Vollenweider FX - Search Results

1

Psychedelics and fNIRS neuroimaging: exploring new opportunities.

Scholkmann F, Vollenweider FX. Scholkmann F, et al. Among authors: vollenweider fx. Neurophotonics. 2023 Jan;10(1):013506. doi: 10.1117/1.NPh.10.1.013506. Epub 2022 Dec 2. Neurophotonics. 2023. PMID: 36474478 Free PMC article.

2

Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia.

Ludewig K, Geyer MA, Etzensberger M, Vollenweider FX. Ludewig K, et al. Among authors: vollenweider fx. Schizophr Res. 2002 May 1;55(1-2):129-37. doi: 10.1016/s0920-9964(01)00198-0. Schizophr Res. 2002. PMID: 11955972

3

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).

Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Vollenweider FX, et al. Eur Neuropsychopharmacol. 1997 Feb;7(1):25-38. doi: 10.1016/s0924-977x(96)00042-9. Eur Neuropsychopharmacol. 1997. PMID: 9088882 Clinical Trial.

4

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Vollenweider FX, et al. Neuropsychopharmacology. 1997 May;16(5):357-72. doi: 10.1016/S0893-133X(96)00246-1. Neuropsychopharmacology. 1997. PMID: 9109107

5

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Vollenweider FX, et al. Among authors: vollenweider scherpenhuyzen mf. Neuroreport. 1998 Dec 1;9(17):3897-902. doi: 10.1097/00001756-199812010-00024. Neuroreport. 1998. PMID: 9875725 Clinical Trial.

6

[The drug emergency].

Vollenweider-Scherpenhuyzen MF, Vollenweider FX. Vollenweider-Scherpenhuyzen MF, et al. Among authors: vollenweider fx. Anaesthesist. 1998 Nov;47(11):946-55. doi: 10.1007/s001010050650. Anaesthesist. 1998. PMID: 9870095 Review. German. No abstract available.

7

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Vollenweider FX, et al. Eur Neuropsychopharmacol. 1997 Feb;7(1):9-24. doi: 10.1016/s0924-977x(96)00039-9. Eur Neuropsychopharmacol. 1997. PMID: 9088881 Clinical Trial.

8

Correction: Mapping brain-behavior space relationships along the psychosis spectrum.

Ji JL, Helmer M, Fonteneau C, Burt JB, Tamayo Z, Demšar J, Adkinson BD, Savić A, Preller KH, Moujaes F, Vollenweider FX, Martin WJ, Repovš G, Cho YT, Pittenger C, Murray JD, Anticevic A. Ji JL, et al. Among authors: vollenweider fx. Elife. 2022 Apr 5;11:e79129. doi: 10.7554/eLife.79129. Elife. 2022. PMID: 35380951 Free PMC article.

9

Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.

Vollenweider FX. Vollenweider FX. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:92-103. doi: 10.1055/s-2007-979353. Pharmacopsychiatry. 1998. PMID: 9754840 Review.

10

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.

Liechti ME, Baumann C, Gamma A, Vollenweider FX. Liechti ME, et al. Among authors: vollenweider fx. Neuropsychopharmacology. 2000 May;22(5):513-21. doi: 10.1016/S0893-133X(99)00148-7. Neuropsychopharmacology. 2000. PMID: 10731626 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

149 results

Search Page